Filament Health today announced that it has grown its 20th cultivar of psilocybin-containing mushrooms. The cultivation was conducted at its Vancouver-based GMP facility, at which current production “yields the equivalent of over 25,000 therapeutic doses of psilocybin per year.” Filament has now grown and analysed 20 varieties of psychoactive mushrooms, with 75 undergoing screening. Ryan Moss…


Previous articleMindMed Announces Chief Executive Officer Transition
Next articleMYND Life Sciences Announces Patent Applications for Depression and Neuropsychiatric Disorder Drugs